HHS's six-peptide policy is still a draft, and its comment window closed November 13, 2026. One form letter accounts for 104 of 115 published HHS peptide policy comments. HHS is the U.S. Department of Health and Human Services; peptides are short chains of protein building blocks.

As of November 19, 2026, the day this article was written, the public record still shows the draft, with no final policy published. The October 30 Federal Register notice describes a draft that does not bind HHS or the public. Compounding means preparing medicine for an individual prescription.

The American Medical Association published its opposition November 18. That position sits outside Promise's count of published comments, alongside other organizations' letters.

Who has asked HHS to stop?

As of November 19, 2026, the day this article was written, these organizations have released their own positions outside the published comment set.

Asked HHS to withdraw or not proceed:

  • American Medical Association: its November 18 release urges withdrawal; “We should not bypass the science and put patients at risk by making them guinea pigs for unapproved drugs,” its president says.
  • Endocrine Society: its November 13 letter asks HHS “not to move forward with this interim policy,” citing insufficient clinical evidence.
  • American Academy of Family Physicians: its November 11 letter says quality safeguards “cannot replace the need for evidence” of safety and effectiveness.
  • American Pharmacists Association: its November 13 comment asks HHS to “withdraw the current enforcement discretion policy” while FDA, the U.S. drug regulator, completes its review.
  • Public Citizen: its November 13 comment urges HHS to “reconsider and not implement” the policy.
  • Partnership for Safe Medicines: its November 13 announcement describes its comment as “opposing” the proposal; its earlier citizen petition is covered in our HHS policy explainer.

Supported the pathway with recommendations:

  • National Community Pharmacists Association and Alliance for Pharmacy Compounding: their November 17 announcement supports a pathway “under defined conditions,” seeking clearer sourcing, reporting and state-regulator communication.

The underlying treatment evidence remains separate. The 2021 BPC-157 knee-pain paper in Alternative Therapies in Health and Medicine looked back at patient records. That design cannot establish whether treatment caused improvement.

What the HHS peptide policy comments show

As of November 19, 2026, the day this article was written, docket HHS-OASH-2026-0496 had received 289 submissions. Only 115 were published. The other 174, or 60%, were not public yet.

All published comments were received October 30–November 6. Nothing received November 7–13, the final week, was public. None of the organizations' letters listed above appears among these 115.

Of the published comments, 104 (90%) use one form letter: 101 are identical, and three make small changes. Only 11 (10%) are independently written. The copies arrived November 5–6: 94 on the first day and 10 on the second.

The letter thanks HHS and asks it to add thymosin alpha-1, kisspeptin-10 and ipamorelin. It also asks HHS to publish its selection criteria. Each requested addition appears in 104 comments.

On November 5, the Alliance for Natural Health USA published an action alert asking readers to post a comment on the official docket; its article names the same three peptides. Neither the alert page nor the published docket shows who wrote or circulated the letter, so the shared timing and peptides do not establish its source.

Who submitted the published comments:

Who Comments
Individuals who stated no professional role (104 form-letter submitters + 6 others) 110
Clinic or telehealth businesses (a telehealth company's cofounder; a men's health clinic's owner-clinician) 2
A state-licensed compounding pharmacy 1
A pharmacist writing as an individual (a former state pharmacy-board inspector) 1
A company being formed to test peptide products 1
Drug manufacturers, medical societies, trade associations, patient or consumer groups, academic researchers 0

What positions they took:

Position Comments Of which form letter
Support it and ask HHS to go further (more peptides, a longer-lasting policy, or easier access) 106 104
Support it as drafted 3 0
Support it and ask for added or stronger safeguards (testing, standards, more research) 2 0
Neither for nor against: asks HHS to clarify the policy's legal standing 1 0
Object that it is too restrictive 1 0
Ask HHS to withdraw it 2 0

Independent comments raised testing standards, the relationship between federal policy and state rules, and questions about the single-ingredient condition. Those are commenters' concerns, not findings about treatment.

Comments cannot settle treatment safety. The original MOTS-c paper in Cell Metabolism, 2015 reported treatment experiments in mice. Those results cannot establish benefits or long-term safety for people.

What the count cannot tell you

This is an early, incomplete set: it covers only what HHS had published by November 19, 115 of 289 submissions, all received in the first week. The unpublished 174 submissions may look very different. Medical societies’ public opposition letters are not among the 115 published comments.

A comment count is not a vote. Agencies weigh arguments and evidence; 104 copies of a letter make one argument. The docket does not show who organized that letter, and this count does not try to.

Sorting comments involves judgment. The independent coding passes differed on 1 of 15 distinct texts for “who” and 1 of 15 for “position.” People were counted by the role they stated. Someone stating none could still be a clinician, patient or industry worker.

How we counted

We read every comment published on docket HHS-OASH-2026-0496 as of November 19, 2026: 115 submissions. Identical texts were grouped, which left 15 distinct texts. Each distinct text was categorised twice, independently, by two different AI models working from the same written codebook, for who was writing and what position they took. The two passes agreed on 14 of 15 texts for each question, and the two differences were settled by re-reading the comment. Individual commenters are not named here. The comments themselves are public on regulations.gov.

Promise is a telehealth company, and prescriptions written through its prescriber network are filled by licensed U.S. compounding pharmacies. Promise therefore has a commercial interest in federal compounding policy. This count reports what the published comments say and takes no position on the policy.

A note on compounded medication

BPC-157 prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.

What happens next?

HHS may finalize, revise or withdraw the draft. The 503A bulks list, the federal list of raw ingredients for patient-specific compounding, follows separate rulemaking. Our FDA decision history and interim-access filing history explain the earlier steps.

As of November 19, 2026, the day this article was written, Kentucky's November 19 board alert reports a November 18 vote declining waivers. It directs pharmacies not to compound, dispense or ship these preparations in or into Kentucky. State actions need separate attention.

At Promise, a licensed provider reviews every request, and not everyone qualifies. A comment letter cannot decide whether a treatment fits a person's health history.

A licensed provider may still prescribe — that decision is between you and your doctor.